摘要
目的利用大样本的真实世界数据,分析头孢哌酮钠/舒巴坦钠相关严重过敏反应发生情况及其影响因素。方法借助"医疗机构药品不良事件(adverse drug events,ADE)主动监测与智能评估警示系统"(ADE-ASAS)回顾性自动监测解放军总医院2013年7月至2018年6月使用注射用头孢哌酮钠/舒巴坦钠的住院患者,双人评价系统报警病例,获得头孢哌酮钠/舒巴坦钠相关严重过敏反应的发生率与特征,并进行影响因素分析。结果 31 684例次用药患者发生严重过敏反应28例,发生率为0.88‰。多因素Logistic回归分析显示,过敏史(OR=4.861,95%CI:1.88312.546)、风湿免疫疾病(OR=4.611,95%CI:1.75312.127)为头孢哌酮钠/舒巴坦钠致严重过敏反应的影响因素。结论头孢哌酮钠/舒巴坦钠相关严重过敏反应发生率属罕见范围。详询患者过敏史、既往史有助于降低临床用药风险。
Objective The occurrence and influencing factors of severe allergic reactions related to cefoperazone/sulbactam sodium were analyzed by using large sample of the real world data.Methods With the help of "the adverse drug events active surveiuance and assessment system(ADE-ASAS)in medical institutions",the inpatients used cefoperazone/sulbactam sodium for injection in the General Hospital from July 2013 to June 2018 were retrospected.The alarm cases were evaluated by double person system,and the incidence and occurrence characteristics of serious allergic reactions related to cefoperazone/sulbactam sodium were obtained,and the influencing factors were analyzed.Results Totally 28 cases of severe allergic reaction occurred in 31684 cases,the incidence rate was 0.88 ‰.Multivariate logistic regression analysis showed that allergic history(OR=4.861,95% CI:1.883-12.546)and rheumatic immune disease(OR= 4.611,95% CI:1.753-12.127)was the influencing factor of severe allergic reaction induced by cefoperazone/sulbactam sodium.Conclusion The incidence of severe allergic reactions related to cefoperazone/sulbactam sodium is rare.Detailed inquiry of allergy history and past history could help to reduce the risk of clinical medication.
作者
栗啸阳
郭代红
刘思源
杨鸿溢
姚翀
LI Xiao-yang;GUO Dai-hong;LIU Si-yuan;YANG Hong-yi;YAO Chong(Deyarment of Pharmacy,Medical Security Center of PLA General Hospital,Bejing 100853,China;School of Pharmacy,Chongqing Medical Urirersity,Chongqing 400016,China)
出处
《临床药物治疗杂志》
2021年第1期54-57,共4页
Clinical Medication Journal
基金
2017年军事医学创新工程重点项目(17CXZ010)。
